A

ACADIA Pharmaceuticals
D

ACAD

21.770
USD
0.23
(1.07%)
مفتوح الان
حجم التداول
28,585
الربح لكل سهم
0
العائد الربحي
-
P/E
16
حجم السوق
3,641,793,878
أصول ذات صلة
ABBV
ABBV
1.160
(0.64%)
183.380 USD
ALNY
ALNY
-2.57
(-0.89%)
286.78 USD
AMGN
AMGN
-0.57
(-0.21%)
271.01 USD
BIIB
BIIB
-0.740
(-0.59%)
125.550 USD
BMRN
BMRN
-0.610
(-1.05%)
57.380 USD
INCY
INCY
-0.050
(-0.08%)
64.450 USD
NBIX
NBIX
0.710
(0.60%)
119.800 USD
S
SAGE
-0.08000
(-1.21%)
6.52000 USD
S
SRPT
-0.880
(-2.27%)
37.920 USD
X
XNCR
-0.16000
(-2.08%)
7.53000 USD
المزيد
الأخبار المقالات

العنوان: ACADIA Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.